logo
GEHealthCareAnnouncesFirstPatientDosedinPhase2/3LUMINATrialforManganese-BasedMRIContrastAgentUnderFDAFastTrackDesignation,FurtherAdvancingItsInnovationPipelineofNovelImagingAgents
===2026/4/24 10:39:04===
s present in our food, and is an endogenous element, naturally occurring and autoregulated in the body. The macrocyclic ‘cage-like’ structure of mangaciclanol lessens the possibility of retention.

Approximately one-third of global MRI procedures require a contrast agent for effective diagnosis,1with around 65 million gadolinium contrast enhanced procedures globally each year.2As a rare-earth element, gadolinium supply is largely dependent on mining and processing infrastructure in China. Manganese, however, is abundantly available from multiple countries, including South Africa, Australia and Gabon, reducing the risk of supply challenges impacting patient care. Furthermore, as manganese is naturally found in water sources, mangaciclanol could also reduce environmental concerns associated with post-patient excreted contrast media in groundwater.

Dr Jit Saini, Chief Medical Officer, Pharmacutical Diagnostics, GE HealthCare, said, “Existing gadolinium
=*=*=*=*=*=
当前为第3/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页